Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial (TACTIC)

7. september 2026 opdateret af: University Hospital, Toulouse

Immunocompromised individuals, such as patients with multiple sclerosis (MS) or diseases of the neuromyelitis optica spectrum (NMOSD) treated with an anti-CD20 monoclonal antibody, present an increased risk of shingles. The immunogenicity - and therefore the clinical effectiveness - of the recombinant vaccine against the varicella zoster virus based on glycoprotein E, recently recommended according to two-dose schedule two months apart in immunocompromised patients aged ≥ 18 years, could be significantly decreased when administered one month before and one month after the infusion of anti-CD20.

We hypothesize that, in patients with MS or NMOSD treated with anti-CD20 administered every six months, a two-dose M0-M6 vaccination schedule consisting of deferring the second dose six months after the first infusion, that is, five months after the anti-CD20 infusion, could improve vaccine immunogenicity and, consequently, the effectiveness of the vaccine.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Shingles, caused by reactivation of varicella zoster virus (VZV), is a common condition in immunocompromised people. Its prevention, which has long remained a medical need unmet among these patients, was improved thanks to the availability of the recombinant glycoprotein-based VZV vaccine E (gE). Based on demonstrated clinical efficacy and safety profile in the general population as well as in immunocompromised patients, this vaccine is recommended in France according to a two-person schedule doses spaced two months apart in immunocompromised patients aged ≥ 18 years. However, further studies are needed in order to optimize vaccination strategies according to the different types of immunosuppression.

Patients with MS or NMOSD, who are at increased risk of herpes zoster, are extensively treated with anti-CD20 monoclonal antibodies, which are known to significantly alter immune responses to vaccines, in particular when vaccination is carried out early after the infusion of anti-CD20.

We hypothesize that in patients with MS or NMOSD treated with anti-CD20 administered every six months, a two-dose M0-M6 vaccination schedule, consisting of deferring the second dose to six months after the first, that is, five months after the anti-CD20 infusion, could improve vaccine immunogenicity and, consequently, the effectiveness of the vaccine.

In this phase IV randomized, controlled, open-label, parallel-group trial, we will compare, within a homogeneous population of patients with MS or NMOSD receiving antiCD20, the humoral response induced by a two-dose vaccination schedule administered at 2 months (M0-M2, "2-month" or standard group) or 6 months (M0-M6, "6-month" or experimental group). After the screening and inclusion phase, patients randomized to the M0-M2 (standard) and M0-M6 (experimental) groups will receive a first dose of recombinant herpes zoster vaccine (RZV) one month before the next scheduled infusion of anti-CD20 monoclonal antibodies (M1). The second dose of RZV will be given at either 2 months ("2-month group", M2) or 6 months ("6-month group", M6). Patients will receive their usual anti-CD20 monoclonal antibody infusions at the appropriate time M1, M7 and M13. The primary outcome will be evaluated one month after the second vaccine dose (M3 for the "2 months" group and M7 for the "6 months" group). The kinetics, intensity, and persistence of humoral and cellular immune responses, as well as safety, will be analyzed as criteria for secondary judgments during the scheduled follow-up visits until M13.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

160

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

  • Frankrig
      • Besançon, Frankrig, 25 000
        • Jean Minjoz University Hospital
        • Ledende efterforsker:
          • Eric Berger, MD
        • Kontakt:
      • Bordeaux, Frankrig, 33 000
        • Pellegrin Hospital Group
        • Kontakt:
        • Ledende efterforsker:
          • Aurélie Ruet, PHD
      • Caen, Frankrig, 14 033
        • Côte de Nacre University Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Pierre Branger, MD
      • Clermont-Ferrand, Frankrig, 63 000
        • Gabriel Montpied Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Pierre Clavelou, MD
      • Créteil, Frankrig, 94 000
        • GCS CHIC Henri Mondor
        • Ledende efterforsker:
          • Alain Creange, PHD
        • Kontakt:
      • Dijon, Frankrig, 21 000
        • Dijon Hospital University
        • Kontakt:
        • Ledende efterforsker:
          • Thibault Moreau, PHD
      • Grenoble, Frankrig, 38 700
        • Nord Hospital - Grenoble University Hospital
        • Ledende efterforsker:
          • Olivier Casez, MD
        • Kontakt:
      • Libourne, Frankrig, 33 500
        • Libourne Hospital Center
        • Kontakt:
        • Ledende efterforsker:
          • Arnaud Gagnol, MD
      • Lille, Frankrig, 59 037
        • Roger Salengro Hospital - Lille University Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Hélène Zephir, PHD
      • Lille, Frankrig, 59 400
        • Catholics Institut Hospitals Group
        • Kontakt:
        • Ledende efterforsker:
          • Arnaud Kwiatkowski, PHD
      • Lyon, Frankrig, 69 002
        • Lyon Civil Hospices
        • Kontakt:
        • Ledende efterforsker:
          • Sandra Vukusic, PHD
      • Montpellier, Frankrig, 34 295
        • Gui de Chauliac Hospital - Montpellier University Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Xavier Ayrignac, PHD
      • Nantes, Frankrig, 44 800
        • Laennec Hospital
        • Ledende efterforsker:
          • Sandrine Wiertlewski, MD
        • Kontakt:
      • Nice, Frankrig, 06 000
        • Pasteur Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Mikael Cohen, PHD
      • Nîmes, Frankrig, 30 900
        • Nîmes University Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Eric Thouvenot, PHD
      • Paris, Frankrig, 75 012
        • 15/20 Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Dalia Dimitri-Boulos, MD
      • Paris, Frankrig, 75 013
        • Pitié Salpetrière Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Céline Louapre, PHD
      • Paris, Frankrig, 75 019
        • Adolphe de Rothschild Hospital
        • Ledende efterforsker:
          • Marine Boudot de La Motte, MD
        • Kontakt:
      • Poissy, Frankrig, 78 300
        • Intercommunal Hospital Center of Poissy Saint-Germain
        • Ledende efterforsker:
          • Olivier Heinzlef, MD
        • Kontakt:
      • Poitiers, Frankrig, 86 000
        • La Miletrie University Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Amélie Dos Santos, MD
      • Rennes, Frankrig, 35 000
        • Pontchaillou Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Laure Michel, PHD
      • Rouen, Frankrig, 76 000
        • Charles Nicolle Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Maxime Guillaume, MD
      • Toulouse, Frankrig, 31 300
        • Purpan Hospital
        • Ledende efterforsker:
          • Jonathan Ciron, MD
        • Kontakt:
      • Tours, Frankrig, 37 000
        • Tours Hospital University
        • Ledende efterforsker:
          • Inès Doghri, MD
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • Patients with Multiple Sclerosis (any clinical form) or Neuromyelitis optica spectrum disease seropositive for aquaporin-4 antibodies (AQP4+)
  • Aged 18 years or more
  • Treated with anti-CD20 mAbs (Rituximab IV or Ocrelizumab IV or SC) since < 2 years with dosing intervals of 6 months (and for Rituximab, treated with 1g per infusion)
  • Planned to receive the same anti-CD20 mAbs with dosing intervals of 6 months during the 13 months of the study (and for Rituximab, planned to receive 1g per infusion)
  • Known history in the medical file of varicella, or VZV IgG serology known to evidence a prior infection
  • Affiliated or beneficiary of a social security scheme
  • Written and informed consent
  • Understands and agrees to comply with the study procedures

Exclusion Criteria:

  • Temporary contraindication to vaccination (concurrent episode of acute fever >38.5°C)
  • Shingles in the last 12 months or VZV vaccination in the last 5 years
  • Patients already treated or supposed to be treated with Ofatumumab (another anti-CD20 mAbs but delivered with a monthly subcutaneous injection)
  • Patients who received high dose corticosteroids (methylprednisolone at a dose of ≥ 500 mg, administered over 1 to 5 days) in the 3 months prior to inclusion
  • Patients who have been exposed to Cladribine in the prior 12 months
  • Patients who received or were scheduled to receive any vaccination, except for influenza and SARS-CoV-2 vaccines during the epidemic season, within 2 weeks prior to the 2 RZV injections and up to 4 weeks after the second RZV injection
  • Hypersensitivity to the active substance or to one of the excipients
  • Patient protected by the law (guardianship, curatorship)
  • Pregnancy or breast-feeding
  • Women of childbearing potential (WOCBP) without effective contraception throughout the duration of the trial
  • Criteria related to the use of ancillary anti-CD20 treatments (Rituximab and Ocrelizumab):

Hypersensitivity to the active substance or to any of the excipients Severe, active infections Severe immunodeficiency Severe heart failure or severe uncontrolled heart disease Known progressive malignancies

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: 2 months arm
Patients will receive the standard vaccination schedule in two doses in 2 months.
Biologisk: Two-dose M0-M2 vaccination schedule

Patients randomized to the "2 months" vaccination group will receive their first dose of RZV vaccine one month before the next scheduled infusion anti-CD20 monoclonal antibody (M0 corresponding to the visit during the first dose of vaccine, M1 at the time of scheduled anti-CD20 infusion).

The second dose of RZV vaccine will be administered 2 months later. Patients will receive their regular anti-CD20 infusions at times M1, M7, and M13.
Eksperimentel: 6 months arm
Patients will receive a vaccination schedule in two doses in 6 months.
Biologisk: Two-dose M0-M6 vaccination schedule

Patients randomized to the "6 months" vaccination group will receive their first dose of RZV vaccine one month before the next scheduled infusion anti-CD20 monoclonal antibody (M0 corresponding to the visit during the first dose of vaccine, M1 at the time of scheduled anti-CD20 infusion).

The second dose of RZV vaccine will be administered 6 months later. Patients will receive their regular anti-CD20 infusions at times M1, M7, and M13.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Humoral vaccine response rate for IgG anti-VZV gE response
Tidsramme: 3 months for the " 2 months " group and 7 months for the " 6 months " group
It will be defined as the proportion of patients with at least a 4-fold increase in anti-VZV gE antibody titers (measured by ELISA) at 1 month after the 2nd vaccine dose compared to baseline (M0), or seroconversion for those who were seronegative at M0.
3 months for the " 2 months " group and 7 months for the " 6 months " group

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The humoral response in terms of Geometric Mean Titer (GMT) at 1 month after the 2nd vaccine dose.
Tidsramme: 3 months for the " 2 months " group and 7 months for the " 6 months " group

It will be assessed by the ratio (M0-M6 versus M0-M2 groups) of the adjusted Geometric Mean Titer (GMT) of anti-VZV gE IgG at 1 month after the 2nd vaccine dose.

The adjusted GMT will correspond to the GMT at 1 month after the 2nd vaccine dose conditionally to the means of the log transformed GMT before vaccination at baseline (M0) calculated across the treatment groups.
3 months for the " 2 months " group and 7 months for the " 6 months " group
Composite criteria of the humoral response up to M13
Tidsramme: 13 months
The kinetics, intensity and persistance will be assessed by the Geometric Mean Titer (GMT) of anti-VZV gE IgG measured at baseline (M0) and up to M13: before the 2nd vaccine dose, 1 month after the 2nd vaccine dose, and prior to the next anti CD20 infusions at M7 and M13.
13 months
Composite criteria of the cellular response at 1 month after the 2nd vaccine dose
Tidsramme: 3 months for the " 2 months " group and 7 months for the " 6 months " group

It will be assessed by the cellular vaccine response rate for gE-specific CD4[AIM+] T response measured 1 month after the 2nd vaccine dose.

The cellular VRR is defined as the proportion of patients with a proportion of gE-specific CD4[AIM+] T cells at least 2 times above the cutoff after vaccination.

The proportion of gE-specific CD4[AIM+] T cells among CD4 T cells is defined by the proportion of CD4 T cells expressing at least one Activation-Induced Marker (AIM), as detected by flow cytometry, following in vitro stimulation with a peptide pool covering the entire ectodomain of gE. The AIM include CD69, CD25, OX40, CD40L, and CD137. We will determine the cut-off of gE-specific CD4[AIM+] T cells by assessing cellular immune responses across a range of non-vaccinated, healthy individuals.
3 months for the " 2 months " group and 7 months for the " 6 months " group
Composite criteria of the cellular response at M13
Tidsramme: 13 months
The kinetics, intensity and persistance of the cellular response up to M13 will be assessed by the proportion of gE-specific CD4[AIM+] T cells among CD4 T cells measured at baseline (M0) and up to M13 : before the 2nd vaccine dose, 1 month after the 2nd vaccine dose, and prior to the next anti-CD20 infusions at M7 and M13.
13 months
The vaccine safety
Tidsramme: from M0 to month 13
The safety will be assessed by the adverse events including serious adverse events collected during the study.
from M0 to month 13

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Composite criteria of the predicted humoral response at M20
Tidsramme: 20 months

Predicted humoral vaccine response rate will be assessed by the predicted humoral vaccine response rates at M20 of the M0-M6 RZV vaccine schedule ("6 months" group) and the M0-M2 RZV vaccine schedule ("2 months" group).

Anti-VZV gE IgG at M20 will be assessed by the adjusted Geometric Mean Titers of anti-VZV gE IgG at M20 of the M0-M6 RZV vaccine schedule ("6 months" group) and the M0-M2 RZV vaccine schedule ("2 months" group).
20 months
The overall predicted humoral exposure from M0 to M20
Tidsramme: 20 months
It will be assessed by the areas under the curve (AUC) of anti-VZV gE IgG titers between M0 and M20 of the M0-M6 RZV vaccine schedule ("6 months" group) and the M0-M2 RZV vaccine schedule ("2 months" group).
20 months
The predicted cellular response at M20
Tidsramme: 20 months
It will be assessed by the predicted cellular vaccine rate response proportions of gE specific CD4[AIM+] T cells among CD4 T cells of the M0-M6 RZV vaccine schedule ("6 months" group) and the M0-M2 RZV vaccine schedule ("2 months" group).
20 months
The overall predicted cellular exposure from M0 to M20
Tidsramme: 20 months
It will be assessed by the areas under the curve (AUC) of gE-specific CD4[AIM+] T cells among CD4 T cells between M0 and M20 of the M0-M6 RZV vaccine schedule ("6 months" group) and the M0-M2 RZV vaccine schedule ("2 months" group).
20 months
Composite criteria of the associated factors with early and persistent, humoral and cellular vaccine responses
Tidsramme: 20 months
The factors which will be studied are : age, sex, number of prior anti-CD20 infusions, type of latest DMT before anti-CD20 therapy, albumin and gammaglobulin levels, Ig G levels, leukocyte counts, T and B cell immunophenotyping, and immune exhaustion and immunosenescence markers throughout the study.
20 months
The correlation between the titers of anti-VZV gE IgG by ELISA and the titers of total IgG anti-VZV by the commercial Diasorin serological test.
Tidsramme: 20 months
It will be assessed by the correlation between ELISA gE titer and the total anti-VZV glycoproteins IgG measured by the Liaison XL® Diasorin serological test.
20 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

University Hospital, Toulouse

Efterforskere

  • Ledende efterforsker: Jonathan Ciron, MD, University Hospital, Toulouse

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

20. oktober 2026

Primær færdiggørelse (Anslået)

20. juni 2030

Studieafslutning (Anslået)

30. november 2030

Datoer for studieregistrering

Først indsendt

7. september 2026

Først indsendt, der opfyldte QC-kriterier

7. september 2026

Først opslået (Faktiske)

14. september 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

14. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

7. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • RC31/25/0535
  • 2025 (U.S. NIH-bevilling/kontrakt: Faculty of Social Sciences Scientific Grant at the University of Gdańsk)
  • PHRC 24-0185 (Andet bevillings-/finansieringsnummer: French Ministry of Health)
  • 2025-525106-37-00 (Anden identifikator: ID-RCB)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner